Compare TX & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TX | KYMR |
|---|---|---|
| Founded | 1961 | 2015 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 9.6B |
| IPO Year | 2006 | 2020 |
| Metric | TX | KYMR |
|---|---|---|
| Price | $49.74 | $100.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 26 |
| Target Price | $37.70 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 625.9K | 554.2K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 6.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,211,000.00 |
| Revenue This Year | $9.60 | $10.61 |
| Revenue Next Year | $6.66 | $8.17 |
| P/E Ratio | $20.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.44 | $36.88 |
| 52 Week High | $51.73 | $130.05 |
| Indicator | TX | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 67.18 | 41.38 |
| Support Level | $41.60 | $76.40 |
| Resistance Level | $50.35 | $103.00 |
| Average True Range (ATR) | 1.32 | 4.62 |
| MACD | 0.53 | -2.22 |
| Stochastic Oscillator | 91.67 | 6.92 |
Ternium SA is a flat steel producer operating in Mexico, Brazil, Argentina, Colombia, the southern United States, and Central America. It produces finished and semi-finished steel products and iron ore, which are sold either directly to steel manufacturers and steel processors or end-users. The company operates in two segments: Steel and Mining. In its Steel segment, the company produces slabs, billets & round bars, hot-rolled coils & sheets, bars & stirrups, wire rods, steel pipes, and other products. The Mining segment sells iron ore as concentrates (fines) and pellets. The vast majority of its revenue comes from the Steel segment and geographically from Mexico.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.